Cargando…

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation

INTRODUCTION: Direct current cardioversion (DCCV) is considered as the most effective treatment for atrial fibrillation (AF). AF is associated with an increased risk of thromboembolism, and DCCV may increase this risk. The current recommendation is, therefore, to anticoagulate for at least 3 weeks b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benamer, Sufyan, Lusty, Debbie, Everington, Tamara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125109/ https://www.ncbi.nlm.nih.gov/pubmed/27457612 http://dx.doi.org/10.1007/s40119-016-0067-1

Ejemplares similares

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2015)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation
por: Li, Hongxia, et al.
Publicado: (2021)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: Protocol
por: Duraes, Andre Rodrigues, et al.
Publicado: (2014)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
por: Norby, Faye L., et al.
Publicado: (2017)

Adjunctive Pharmacotherapy for Elective Direct Current Cardioversion in Patients With Atrial Fibrillation
por: Hirt, Liam S., et al.
Publicado: (2012)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Uninterrupted dabigatran is safer than warfarin in patients undergoing ablation for atrial fibrillation
por: Spartalis, Michael, et al.
Publicado: (2017)

Current Status of Internal Cardioversion in Atrial Fibrillation
por: Plewan, Andreas, et al.
Publicado: (2002)

Atrial fibrillation cardioversion following acupuncture
por: Dilber, Dario, et al.
Publicado: (2015)

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
por: Durães, André Rodrigues, et al.
Publicado: (2016)

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
por: You, Joyce H. S., et al.
Publicado: (2012)

Comparison of monophasic versus biphasic cardioversion for atrial fibrillation
por: Vaisman, M, et al.
Publicado: (2005)

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial
por: Lip, Gregory Y. H., et al.
Publicado: (2020)

Ogilvie's Syndrome following Cardioversion for Atrial Fibrillation
por: Al-Halawani, Moh'd, et al.
Publicado: (2014)

Chemical Cardioversion of Atrial Fibrillation with Calcium Gluconate
por: Serhat, A, et al.
Publicado: (2012)

A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
por: Sorensen, Sonja V., et al.
Publicado: (2013)

Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups
por: Gómez-Outes, Antonio, et al.
Publicado: (2013)

Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study
por: Hohnloser, Stefan H., et al.
Publicado: (2019)

Comparison of clinical outcomes of Ibutilide-guided cardioversion and direct current synchronized cardioversion after radiofrequency ablation of persistent atrial fibrillation
por: Liu, Xing, et al.
Publicado: (2023)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

Absence of significant myocardial injury following elective direct current cardioversion for atrial fibrillation
por: Lobo, Ronstan, et al.
Publicado: (2022)

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion
por: Demirel, Ozan, et al.
Publicado: (2023)

The Impact of Right Atrial Size to Predict Success of Direct Current Cardioversion in Patients With Persistent Atrial Fibrillation
por: Döring, Christoph, et al.
Publicado: (2023)

Feasibility and safety of the direct current cardioversion at the time of left atrial appendage occlusion for patients with atrial fibrillation
por: Meng, Xian Sai, et al.
Publicado: (2023)

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
por: Pink, Joshua, et al.
Publicado: (2011)

Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis
por: Providência, Rui, et al.
Publicado: (2014)

Effectiveness and safety of dabigatran versus warfarin in “real-world” Japanese patients with atrial fibrillation: A single-center observational study
por: Naganuma, Miyoko, et al.
Publicado: (2017)

Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011)

Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: A single-center experience
por: Shibata, Naoki, et al.
Publicado: (2017)

Real‐life experience with non‐vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation
por: Itäinen‐Strömberg, Saga, et al.
Publicado: (2020)

Pharmacological cardioversion for atrial fibrillation and flutter
por: Cordina, J, et al.
Publicado: (2006)

Rivaroxaban in atrial fibrillation cardioversion: an update
por: Lavalle, Carlo, et al.
Publicado: (2019)

How to Optimize Cardioversion of Atrial Fibrillation
por: Airaksinen, K. E. Juhani
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_47f127p4i9tlfr8rjpuo3ekaes